Actinogen Seeks ASX Quotation for 60,000 New Shares

Actinogen Medical ( (AU:ACW) ) has issued an announcement.

Actinogen Medical Limited has applied to the ASX for quotation of 60,000 new ordinary fully paid shares, issued on 10 May 2026 under its ticker ACW. The additional securities arise from the exercise or conversion of existing options or other convertible instruments, modestly expanding the company’s share base and providing incremental capital or equity alignment for stakeholders.

The application reflects routine capital management activity as Actinogen advances its operations within the biotech sector. While the issuance is relatively small, it slightly increases liquidity in the company’s stock and may indicate ongoing participation by holders of options or convertible securities, reinforcing engagement from existing stakeholders.

The most recent analyst rating on (AU:ACW) stock is a Buy with a A$0.08 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.

More about Actinogen Medical

Actinogen Medical Limited is an Australian biotechnology company listed on the ASX, focused on developing medical treatments and therapies. The company operates in the life sciences sector and issues ordinary fully paid shares as its primary listed security, targeting investors interested in healthcare and biotech innovation.

YTD Price Performance: -22.95%

Average Trading Volume: 2,817,911

Technical Sentiment Signal: Buy

Current Market Cap: A$168.7M

For detailed information about ACW stock, go to TipRanks’ Stock Analysis page.